{"id":"NCT00928486","sponsor":"Celgene","briefTitle":"A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma","officialTitle":"A Safety Confirmation Study On Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-04-28","primaryCompletion":"2010-09-10","completion":"2010-09-10","firstPosted":"2009-06-26","resultsPosted":"2016-06-14","lastUpdate":"2019-11-20"},"enrollment":25,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Myeloma"],"interventions":[{"type":"DRUG","name":"Lenalidomide","otherNames":["CC-5013","Revlimid"]},{"type":"DRUG","name":"Dexamethasone","otherNames":["Decadron"]}],"arms":[{"label":"Lenalidomide and Dexamethasone","type":"EXPERIMENTAL"}],"summary":"To evaluate the safety and efficacy of lenalidomide with dexamethasone in Japanese patients with previously treated multiple myeloma.","primaryOutcome":{"measure":"Number of Participants Experiencing Treatment-Emergent Adverse Events (TEAE)","timeFrame":"Day 1 of study drug through 28 days after the last dose of study drug; maximum treatment duration was 60.3 weeks","effectByArm":[{"arm":"Lenalidomide and Dexamethasone","deltaMin":25,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":20},"locations":{"siteCount":8,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":25},"commonTop":["Neutropenia","Lymphopenia","Leukopenia","Thrombocytopenia","Constipation"]}}